Enzymotec: PS The Next Big Thing in Nutraceuticals

635974377646600201EnzyPS.jpg

28 Apr 2016 --- Phosphatidylserine – more commonly known as PS – is set to break out from the cognitive health category and make a big impact in several new benefit areas, according to Enzymotec, the supplier of EnzyPS. Until now, PS has been widely used to maintain and improve brain function in a range of applications. But now its benefits are beginning to gain recognition in other areas, too, including skin health, sports nutrition, stress reduction and mood enhancement.

Dr Ariel Katz, President & CEO of Enzymotec, said: “PS is a health ingredient with a really big future. It’s got so much to offer: it’s natural, it’s clinically proven and if you source the right grade or format you can use it in pretty much any food, drink or supplement product. It will continue to be strongly associated with cognitive health, but wider awareness of its benefits will mean that at last PS can reach its full potential.” 

“With EnzyPS, we offer a high quality and effective PS brand that can help supplements companies win customers in new categories.”

Clinical studies have demonstrated that supplementation with PS strengthens the brain cell structure and significantly improves memory, decision-making and mental flexibility. Its effects are long-term and without any side-effects. However, studies have also demonstrated health benefits in a number of other categories, as follows: 

Skin health – Studies have shown that ingestion of PS promotes the development of collagen, which naturally contributes to strengthening and protecting the skin. Supplementation with PS has also been shown to restore the skin’s moisture balance, promote a smooth skin texture and improve overall complexion.

Sports nutrition – In studies involving cycling, running, weightlifting and soccer, PS has been shown to increase time to exhaustion by up to 30% and to reduce muscle soreness by as much as 50%, enabling faster recovery. PS has been shown to reduce the levels of cortisol (a harmful hormone) produced by the body and increase levels of testosterone (a beneficial hormone), thereby promoting muscle recovery. 

Stress reduction – Cortisol is known as the ‘stress hormone’ and it spikes following mental and physical stress. For 25 years it has been known that PS reduces cortisol levels in both blood and saliva. In clinical studies, PS has been shown to reduce the increase in cortisol levels that is caused by typical stressful experiences, such as a job interview or a maths exam. 

Mood enhancement – Cortisol levels also increase when a person is depressed. In a clinical study of elderly people, the control group reported a nearly 30% increase in their depression symptoms after 12 weeks, compared with a group using PS supplementation over the same period.

EnzyPS is supplied in a range of patented formats to suit any application. As well as formulations for dietary supplement tablets, available options include a fine powder that is highly soluble in beverages and mixes well with protein and other powders. Also available is a granulated version with no taste or smell that is perfect for food applications, including chocolate and snacks. 

Enzymotec also supplies a unique PS ingredient derived from sunflowers – most PS ingredients are extracted from soy – which is ideal for softgel capsules.

Dr Katz added: “We believe PS could be the next big thing in the global nutraceutical market. It offers a perfect combination of versatility and efficacy and is truly the perfect nutritional ingredient for today’s sophisticated and health-conscious consumers.”

Enzymotec will showcase its range of EnzyPS solutions at Vitafoods Europe 2016 in Geneva, 10-12 May.

To contact our editorial team please email us at editorial@cnsmedia.com

Enzymotec

Collapse

Who We Are

Enzymotec develops and manufactures nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies. Since its establishment in 1998, the company has enjoyed accelerated growth, generating impressive sales worldwide, by launching a diverse portfolio of innovative products. Our two business segments leverage our lipid-related expertise: Nutrition and Pharma.

Enzymotec's diverse range of products span the entire human life-cycle - from infancy to old age, providing key ingredients for use in infant formula and nutritional supplements, as well as branded medical foods.

Enzymotec's multi-disciplinary team, including scientists, engineers and business development professionals, have an outstanding track-record in turning advanced lipid science into commercially attractive, nutritional solutions, constantly enriching our unique cluster of technology and expertise.

What We Do

We develop clinically-validated products including bio-functional, lipid-based compounds that address a wide spectrum of growing consumer demands, such as optimal development, supplementation for nutritional deficiencies and needs, and the management of medical disorders and diseases.

The comprehensive solutions we develop and manufacture are sold to major consumer companies through our global sales and marketing infrastructure.

How We Do It

We employ proprietary technologies to modify lipids harvested from natural sources, transforming these raw materials into unique and clinically-proven lipid based products. These products are familiar to the human body and possess beneficial secondary characteristics, such as extended shelf life and improved scent or taste profile.

Our Source of Competitive Advantage:

• Safe and clinically-proven products supported by proprietary technology and R&D expertise.

• Experienced leadership and scientific advisory boards.

• Diversified business model

• Strong customer relationships and partnerships

• Integrated scalable platform and product offering, based on state-of-the-art production capabilities.

Related Articles

Packaging & Technology News

Consumer interest in liquid nutraceutical delivery forms grow as “pill fatigue” perseveres, says Bormioli Pharma 

13 Nov 2018 --- Consumers are more mindful of their health and nutraceutical products have become aspects of an everyday diet. This, coupled with a faster pace of consumer living has spurred a number of packaging innovations for nutraceuticals. This is according to Elena Piazza, Business Development & Marketing Manager at Bormioli Pharma, which supplies pharmaceutical and nutraceutical packaging solutions. Its portfolio includes a dual chamber system packaging which offers precise reconstitution for oral products, including food supplements.

Health & Nutrition News

Weekly Roundup: CJ CheilJedang expands Indonesia plant, Valensa hosts expert panel on saw palmetto

09 Nov 2018 --- This week in nutrition, CJ CheilJedang has expanded its Indonesia Jombang plant with a new production line, while Advanced Organic Materials is expanding its manufacturing operations into Spain. OmniActive Health Technologies CurcuWIN and Lutemax 2020 both gained US Pharmacopeia (USP) verification, and Valensa International appointed Sendhil Pani to lead its microalgae market expansion. Valensa also hosted an expert panel yesterday to examine the damage to saw palmetto extract’s sustainability following recent hurricane damage in the Florida area.

Health & Nutrition News

Euphoria: Researchers pinpoint cannabidiol’s safe pain relief mechanism

25 Oct 2018 --- Scientists at the Canadian Research Institute of the McGill University Health Centre (MUHC) and McGill University have pinpointed the effective dose of marijuana plant extract cannabidiol (CBD) for safe pain relief without the typical “high” or euphoria produced by the THC, further underlining the compound’s potential in offering relief to chronic pain sufferers.

Health & Nutrition News

Benexia eyes EU Novel Food approval on two proprietary chia seed extracts

23 Oct 2018 --- The Chilean company Functional Products SA, with its brand Benexia Advanced Seed Nutrition, is awaiting two EU Novel Food approvals on its proprietary extract from chia seed: Chia Protein and Chia Fiber. The company tells NutritionInsight that they shall have the approval in the first semester of 2019.

Health & Nutrition News

Gummy delivery form: Sirio opens new plant to respond to Western demand

19 Oct 2018 --- Sirio Pharma, the global nutraceutical contract development and manufacturing organization (CDMO), is opening a gummy production plant at its new development and manufacturing facility in Ma’anshan, 300km west of Shanghai, China. The news comes 11 years after Sirio opened its first gummy facility and the move responds to increasing market demand for the popular delivery form. As consumers become more discerning, companies will seek out specialist gummy development partners, Rui Yang, CSO of Sirio, predicts.

More Articles
URL : http://www.nutritioninsight.com:80/news/Enzymotec-PS-The-Next-Big-Thing-in-Nutraceuticals.html